Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib with Paclitaxel/Ramucirumab in Second-Line Advanced Gastric or Esophageal Adenocarcinoma
NCT07594548Phase 1Not yet recruiting
- Sponsor
- Northwestern University
- Start
- Sep 2027
- Primary completion
- Sep 2030
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of futibatinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Northwestern University. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose up to 2 years. Planned start Sep 2027; status: not yet recruiting.
02
Drugs
futibatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07594548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594548.